Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma
- 338 Downloads
Oncogenic N-MYC (MYCN) is widely used as a biomarker in clinics for neuroblastoma (NB) patients; nevertheless, mechanism that underlines MYCN regulation remains elusive. In the present study, we identified calreticulin (CRT) as a novel MYCN suppressor that downregulated MYCN promoter activity and protein expression to modulate neuronal differentiation and stemness. Our data showed that CRT-mediated MYCN suppression led to increased neurite length and commensurate elevation in differentiation marker GAP-43. We examined effect of radiotherapy and discovered that ionizing radiation (IR) was able to augment CRT expression dose-dependently in NB. Interestingly, neuronal differentiation and neurosphere formation (NSF) of NB were not only co-modulated by IR and CRT but were also dependent on Ca2+-buffering domain (C-domain) of CRT. Mutagenesis analysis showed that C-domain was indispensable for CRT-mediated MYCN regulation in NB differentiation and NSF. Of note, IR-induced formation of neural stem-like neurospheres (NS) was significantly impaired in CRT-overexpressed NB cells. The occupancy of CRT on MYCN 5′ proximal promoter was confirmed by chromatin immunoprecipitation assays, revealing potential CRT binding sites that coincided with transcription factor E2F1 binding elements. In addition, we identified a physical interaction between CRT and E2F1, and demonstrated that CRT occupancy on MYCN promoter prevented E2F1-mediated MYCN upregulation. In line with in vitro findings, hampered tumor latency and retarded tumor growth in xenograft model corroborated IR and CRT co-mediated neuronal differentiation of NB. Together, our data delineated a novel mechanism of CRT-mediated MYCN regulation and warranted further preclinical investigation towards new therapeutic strategy for NB. CRT suppresses MYCN expression and promotes neuronal differentiation in NB. CRT regulates MYCN via interaction with E2F1 and direct binding to MYCN promoter. Ca2+-buffering domain of CRT is critical in MYCN regulation and NB differentiation. CRT-MYCN axis impacts on NB stemness by modulating neurosphere formation. Xenograft model corroborates in vitro NB differentiation mediated by CRT and IR.
KeywordsCalreticulin Differentiation MYCN Neuroblastoma Neurosphere Radiation
Cancer stem cells
Event-free survival rate
Neural stem cell
Nerve growth factor
Pluripotent stem cells
Transcription start site
We wish to acknowledge Prof. Shin-Ru Shih at Chang Gung University for her kind assistance in general laboratory support. We also appreciate technical support from Microscopy core facility of Chang Gung Memorial Hospital at Linkou.
Conception and design: A.C. Lee, Y.Y. Shih, F. Zhou, Y.F. Liao, W.M. Hsu, J.H. Hong.
Clinical specimen acquisition: Y.Y. Shih, Y.F. Liao, W.M. Hsu.
Data acquisition, analysis, and interpretation: A.C. Lee, Y.Y. Shih, Y.F. Liao, W.M. Hsu.
Development of methodology: A.C. Lee, Y.Y. Shih, F. Zhou, Y.F. Liao, W.M. Hsu.
Technical and conceptual supervision: A.C. Lee, Y.Y. Shih, F. Zhou, H. Lee, Y.F. Liao, W.M. Hsu, J.H. Hong.
Writing and revision of manuscript: A.C. Lee, Y.Y. Shih, F. Zhou, T.C. Chao, H. Lee, Y.F. Liao, W.M. Hsu, J.H. Hong.
This work was supported by medical research grants from Chang Gung Memorial Hospital [CMRPG3F2232, CMRP3G1491, CMRPG3E1301, and CIRPG3D0141] and Ministry of Science and Technology, Taiwan [MOST106-2314-B-182A-023-MY2].
Compliance with ethical standards
Conflict of interest
The authors declare that there is no conflict of interest.
- 5.Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, Children’s Oncology Group (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, Liu T (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29(44):5957–5968CrossRefPubMedGoogle Scholar
- 17.Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, Iraci N, Valli E, Ling D, Thomas W, van Bekkum M, Sekyere E, Jankowski K, Trahair T, Mackenzie KL, Haber M, Norris MD, Biankin AV, Perini G, Liu T (2011) SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 7(6):e1002135CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Chang HH, Lee H, Hu MK, Tsao PN, Juan HF, Huang MC, Shih YY, Wang BJ, Jeng YM, Chang CL, Huang SF, Tsay YG, Hsieh FJ, Lin KH, Hsu WM, Liao YF (2010) Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res 16(17):4411–4420CrossRefPubMedGoogle Scholar
- 26.Shih YY, Nakagawara A, Lee H, Juan HF, Jeng YM, Lin DT, Yang YL, Tsay YG, Huang MC, Pan CY, Hsu WM, Liao YF (2011) Calreticulin mediates nerve growth factor-induced neuronal differentiation. J Mol Neurosci 47(3):571–81Google Scholar
- 27.Pacey LK, Stead S, Gleave J, Tomczyk K, Doering L (2006) Neural stem cell culture: neurosphere generation, microscopical analysis and cryopreservation. Nat Protoc Exch. https://doi.org/10.1038/nprot.2006.215
- 31.Watanabe Y, Ishizuka Y, Hirano T, Nagasaki-Maeoka E, Hoshi R, Yoshizawa S, Uekusa S, Kawashima H, Sugito K, Shinohara K, Fukuda N, Nagase H, Soma M, Koshinaga T, Fujiwara K (2017) ZAR1 knockdown promotes the differentiation of human neuroblastoma cells by suppression of MYCN expression. Med Oncol 34(9):158CrossRefPubMedGoogle Scholar
- 39.Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA (2012) Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21(5):601–613CrossRefPubMedPubMedCentralGoogle Scholar
- 47.Suenaga Y, Islam SMR, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibata T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, Nakagawara A (2014) NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3beta resulting in the stabilization of MYCN in human neuroblastomas. PLoS Genet 10(1):e1003996CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, Liu Q, Perez-Atayde A, Rodig S, Cheung NK, Raynaud F, Hallberg B, Robinson SP, Gray NS, Pearson ADJ, Eccles SA, Chesler L, George RE (2012) The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 22(1):117–130CrossRefPubMedPubMedCentralGoogle Scholar